A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure

2024/10/22 by Kelly S. Chien, Juan José Rodríguez‐Sevilla, Juan Jose Rodriguez-Sevilla +19
Medicine · #Acute Lymphoblastic Leukemia research #Acute Myeloid Leukemia Research #Chronic Myeloid Leukemia Treatments

paper · doi:10.1016/j.leukres.2024.107602

openalex publication_date 2024/10/22 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/27

Citations

• Decitabine improves patient outcomes in myelodysplastic syndromes